News of Filgotinib

Filgotinib has been approved by EMA in Europe for the treatment of adult RA patients. In addition, Filgotinib has been approved by EMA for the treatment of ulcerative colitis (UC), further expanding its indications.

In addition to the completed SELECTION trial, Filgotinib has entered phase 2 research in the treatment of axial spondyloarthritis, psoriatic arthritis, non communicable uveitis, cutaneous lupus, and Sjogren's syndrome, and phase 3 research in the treatment of Crohn's disease (CD).

Filgotinib

Indications： Adult patients with moderate to severe rheumatoid arthritis (RA) who have insufficient or intolerant response to various disease modifying antirheumatic drugs (DMARD).

Scan code
Whatsapp

Medicine-related columns

Recommended Articles

There is no data under this category！

Lucius Pharmaceuticals

Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More